FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2503-2505 June 5, 2008 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Parving, H.-H. PubMed Citation

The discovery 110 years ago that crude kidney extract elicited a pressor reaction provided the first evidence of the existence of the renin–angiotensin–aldosterone system, a major vasoactive system,¹ and the complex actions and interactions of this important cascade are still unfolding. Over the past few decades, various components of the renin–angiotensin–aldosterone system have been elucidated more completely, and previously unknown members have been discovered.² Drugs that specifically block various components of the renin–angiotensin–aldosterone system have been developed (Figure 1). Angiotensin-converting–enzyme (ACE) inhibitors block the conversion of angiotensin I to angiotensin II, and clinically available angiotensin-receptor blockers block the . . . [Full Text of this Article]

This article has been cited by other articles:

• (2008). Beyond Blood Pressure Control: Targeting Proteinuria with Renin-Angiotensin-Aldosterone Inhibitors. Journal Watch Cardiology 2008: 1-1 [Full Text]